I beleive that ASD has their scopes set on a low cost validtion instrument for solid dosage form prescription drugs-that's 90% of the market. No wonder CDEX put their counterfeit drug validation device "on the back-burner".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.